

This policy applies to the following:

Standard Control (SF)	Managed Medicaid Template (MMT)	ACSF Chart (ACSFC)	Medical Benefit	✓	Medicare Part B	Reference #
Standard Control – Choice (SCCF)	Marketplace (MF)	SF Chart (SFC)	Medical: Advanced Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First	4664-D
Preferred Drug Plan Design (PDPD)	Aetna Health Exchange (AHE)	VF Chart (VFC)	Medical Benefit: Managed Medicaid			
Advanced Control Specialty (ACSF)	IVL	New to Market (NTM)	Medical Benefit: Add-on			
Advanced Control Specialty – Choice (ACSCF)	Value (VF)					

EXCEPTIONS CRITERIA HYALURONATES

PREFERRED PRODUCTS (Osteoarthritis-Multi): EUFLEXXA AND SYNVISC
PREFERRED PRODUCTS (Osteoarthritis-Single): DUROLANE AND SYNVISC-ONE

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the hyaluronate products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table 1. Hyaluronate products (Osteoarthritis-Multi)

	Product(s)
Preferred*	<ul style="list-style-type: none"> • Euflexxa (1% sodium hyaluronate) • Synvisc (hylan G-F 20)
Targeted	<ul style="list-style-type: none"> • Gelsyn-3 (sodium hyaluronate) • GenVisc 850 (sodium hyaluronate) • Hyalgan (sodium hyaluronate) • Hymovis (high molecular weight viscoelastic hyaluronan) • Orthovisc (high molecular weight hyaluronan) • Supartz FX (sodium hyaluronate) • Triluron (sodium hyaluronate) • Trivisc (sodium hyaluronate) • Visco-3 (sodium hyaluronate)

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

Table 2. Hyaluronate products (Osteoarthritis-Single)

	Product(s)
Preferred*	<ul style="list-style-type: none"> • Durolane (hyaluronic acid) • Synvisc-One (hylan G-F 20)

This policy applies to the following:

Standard Control (SF)	Managed Medicaid Template (MMT)	ACSF Chart (ACSCF)	Medical Benefit	✓	Medicare Part B	Reference #
Standard Control – Choice (SCCF)	Marketplace (MF)	SF Chart (SFC)	Medical: Advanced Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First	4664-D
Preferred Drug Plan Design (PDPD)	Aetna Health Exchange (AHE)	VF Chart (VFC)	Medical Benefit: Managed Medicaid			
Advanced Control Specialty (ACSF)	IVL	New to Market (NTM)	Medical Benefit: Add-on			
Advanced Control Specialty – Choice (ACSCF)	Value (VF)					

Targeted	<ul style="list-style-type: none"> • Gel-One (cross-linked hyaluronate) • Monovisc (high molecular weight hyaluronan)
-----------------	---

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

II. EXCEPTION CRITERIA

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred product.

A. Osteoarthritis-Multi

Coverage for a targeted product is provided when either of the following criteria is met:

1. Member has received treatment with the requested targeted product in the past 365 days.
2. Member has a documented intolerable adverse event to both of the preferred products, Euflexxa and Synvisc.

B. Osteoarthritis-Single

Coverage for a targeted product is provided when either of the following criteria is met:

1. Member has received treatment with the requested targeted product in the past 365 days.
2. Member has a documented intolerable adverse event to both of the preferred products, Durolane and Synvisc-One.

REFERENCES

1. Durolane [package insert]. Durham, NC: Bioventus, LLC; September 2017.
2. Euflexxa [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; July 2016.
3. Gel-One [package insert]. Warsaw, IN: Zimmer, Inc.; May 2011.
4. Gelsyn-3 [package insert]. Durham, NC: Bioventus LLC; December 2017.
5. GenVisc 850 [package insert]. Doylestown, PA: OrthogenRx, Inc.; November 2019.
6. Hyalgan [package insert]. Florham Park, NJ: Fidia Pharma USA Inc.; August 2017.
7. Hymovis [package insert]. Parsippany, NJ: Fidia Pharma USA Inc.; September 2017.
8. Monovisc [package insert]. Bedford, MA: Anika Therapeutics, Inc.; July 2020.
9. Orthovisc [package insert]. Bedford, MA: Anika Therapeutics, Inc.; November 2021.
10. Supartz FX [package insert]. Durham, NC: Bioventus LLC; April 2015.
11. Synvisc [package insert]. Ridgefield, NJ: Genzyme Biosurgery; September 2014.
12. Synvisc One [package insert]. Ridgefield, NJ: Genzyme Biosurgery; September 2014.
13. Triluron [package insert]. Florham Park, NJ: Fidia Pharma USA Inc.; July 2019.
14. Trivisc [package insert]. Doylestown, PA: OrthogenRX; September 2018.
15. Visco-3 [package insert]. Warsaw, IN: Zimmer Inc.; May 2017.